nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.12.2014 | review

Is there a role for angiogenesis inhibition in prostate cancer?

verfasst von: Isabel Heidegger, MD, PhD, Andreas Pircher, MD, PhD, Assoc. Prof. Jasmin Bektic, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Prostate cancer is the most common male cancer and one of the most common causes of cancer death among men in European countries. In the last years, a large number of new drugs for treatment of castration-resistant prostate cancer (CRPC) have been approved, others are still in an advanced stage of clinical testing. In this review, we provide an overview on new substances which act via modulation or inhibition of angiogenesis. Results and limitations from clinical studies as well as future needs for improvement of those agents in CRPC are critically discussed.

Vorheriger Artikel Angiogenesis inhibition in renal cell cancer

Nächster Artikel Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide curative therapy for acute lymphoblastic leukaemia in children

Jemal A. Global burden of cancer: opportunities for prevention. Lancet. 2012;380:1797–9.PubMedCrossRef

Wong YN, Ferraldeschi R, Attard G, de BJ. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol. 2014;11:365–76.PubMedCrossRef

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.PubMedCrossRef

Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, et al. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol. 2013;138:248–56.PubMedCentralPubMedCrossRef

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRef

Folkman J, Hochberg M. Self-regulation of growth in three dimensions. J Exp Med. 1973;138:745–53.PubMedCentralPubMedCrossRef

Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol. 2014;41:235–51.PubMedCrossRef

Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat. 1995;36:139–55.PubMedCrossRef

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31.PubMedCrossRef

10.

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.PubMedCentralPubMedCrossRef

11.

Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 1999;54:523–7.PubMedCrossRef

12.

George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7:1932–6.PubMed

13.

Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, et al. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999;54:479–85.PubMedCrossRef

14.

Heidegger I, Kern J, Ofer P, Klocker H, Massoner P. Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget. 2014;5:2723–35.PubMedCentralPubMed

15.

Di LG, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54:1089–94.CrossRef

16.

Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011;117:526–33.PubMedCentralPubMedCrossRef

17.

Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534–40.PubMedCentralPubMedCrossRef

18.

Beardsley EK, Hotte SJ, North S, Ellard SL, Winquist E, Kollmannsberger C, et al. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs. 2012;30:1652–9.PubMedCrossRef

19.

Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer. 2007;97:1480–5.PubMedCentralPubMedCrossRef

20.

Aragon-Ching JB, Jain L, Gulley JL, Arlen PM, Wright JJ, Steinberg SM, et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int. 2009;103:1636–40.PubMedCentralPubMedCrossRef

21.

Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, et al. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol. 2012;23:688–94.PubMedCrossRef

22.

Michaelson MD, Oudard S, Ou YC, Sengelov L, Saad F, Houede N, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014;32:76–82.PubMedCrossRef

23.

Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760–8.PubMedCrossRef

24.

Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532–9.PubMedCrossRef

25.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:2070–6.PubMedCentralPubMedCrossRef

26.

Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022–8.PubMedCrossRef

27.

www.clinicaltrials.gov. Accessed: 20 Feb 2014.

28.

Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res. 2012;18:4820–9.PubMedCentralPubMedCrossRef

Titel: Is there a role for angiogenesis inhibition in prostate cancer?
verfasst von: Isabel Heidegger, MD, PhD
Andreas Pircher, MD, PhD
Assoc. Prof. Jasmin Bektic, MD
Publikationsdatum: 01.12.2014
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-014-0187-z

Springer Medizin Österreich

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

International MDS Working Groups: a model of success to improve diagnosis and treatment in rare diseases: 10-year jubilee of the Austrian MDS platform

Lung cancer: ASCO 2014 update

Angiogenesis

Angiogenesis in myeloproliferative neoplasms, new markers and future directions

Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets

ASCO 2014: news, hopes, hypes?